Discussion Guide — Chapter 20

Six prompts, with what to listen for. Each runs 10–20 minutes. Prompts 2 and 4 are the two most likely to produce genuine disagreement, which is what you want.

1. "The receptors were found before the ligands. Why is that a scientific argument and not just a historical accident?"

What to listen for: students should reach the evolutionary inference — a specific, saturable, stereochemically selective binding site is not built for a plant a species may never meet, so its existence predicts an endogenous ligand. Strong groups notice that this is a prediction that could have failed and did not, which is what makes it evidence.

Where it goes wrong: students treat it as a nice story about scientific serendipity. Push back: what would we have concluded if no endogenous ligand had ever been found? Getting them to state the falsifying outcome is the whole exercise.

Bridge: this is the same logic Chapter 5 uses when it asks what would change a rating.

2. "Everyone in this room has a fully functional endogenous opioid system. Why does nobody have pharmacological analgesia?"

What to listen for: the existence proof, arrived at independently. Expect the room to reach for magnitude first ("not enough of it"), then duration ("it doesn't last"), and then — this is the good moment — for someone to notice that the system is not idle at all, that its output is the baseline they experience as ordinary, and that a supplement promising to "unlock" it is promising to exceed a ceiling set by biosynthesis.

Where it goes wrong: students conclude the endogenous system is weak or vestigial. It is not; it is regulated. Redirect to §20.4 — a system that can close the pain gate hard enough to permit surgery is not weak. It is tightly controlled, which is a different thing.

Bridge: this prompt does most of the work of §20.8 before students read the section, if you run it early.

3. "Naloxone reduces placebo analgesia. Write the strongest possible objection to concluding that placebo analgesia is opioid-mediated."

What to listen for: the good objections are (a) naloxone has its own effects on pain sensitivity, so the apparent reversal could be additive rather than blockade; (b) the effect was studied in one pain model; (c) reduction is not abolition. All three appear in the chapter's What it doesn't field, and students who generate them independently have understood the design.

Where it goes wrong: students object that "it's still self-report." Ask them what naloxone does to self-report in the absence of a placebo-released ligand. The objection dissolves and the point lands harder than if you had stated it.

Bridge: prompt 3 and prompt 4 are best run back to back.

4. "The runner's-high claim and the placebo claim have comparably plausible mechanisms. One is ⚠️ and one is ✅. Is that defensible, or is the book being inconsistent?"

What to listen for: the answer is study design, and students should be able to say it in one sentence. What separates a good discussion from a great one is whether anyone argues the other side well — that the imaging evidence for central opioid release during exercise is real, in the right compartment, and arguably stronger than what many ⚠️ ratings rest on elsewhere in the book.

Where it goes wrong: the room agrees too fast. If that happens, assign someone to argue for upgrading the runner's high to ✅ and make them specify what evidence they are leaning on. The exercise of failing to build that case is the lesson.

Facilitator note: it is fine to say the ratings are editorial judgments and that a well-argued disagreement is a good outcome. The book says so itself.

5. "Tolerance, physical dependence, addiction. Define each without using the other two, then say what goes wrong when the last two get conflated."

What to listen for: clean, non-circular definitions first — this is harder than it looks and is worth the time. Then concrete harms with named parties: undertreated pain patients; abrupt discontinuation and withdrawal; patients withholding information from clinicians; stigma; and the obscured clinical picture for people who do have opioid use disorder.

Where it goes wrong: moralized framing. Redirect to mechanism: dependence is a receptor adaptation, and receptors do not consult anyone's intentions. Do not single the student out; the framing is cultural and near-universal, and treating it as a personal error will cost you the rest of the discussion.

Do not let this become: a debate about prescribing policy, drug enforcement, or the opioid crisis as a political subject. Those are real topics and this is not the room for them. The chapter is about peptide pharmacology and its scope is a feature.

6. "Ziconotide has to be pumped into cerebrospinal fluid. What is that a measurement of?"

What to listen for: the barrier. The route of administration is evidence about the obstacle — an approved drug, a company with every commercial incentive to find an easier route, and forty years of delivery research have not produced one. Strong students connect this to §20.8: if a pharmaceutical company with a working molecule cannot get a 25-residue peptide into the CNS, a capsule is not going to.

Where it goes wrong: students treat it as a limitation of one drug rather than as data about a class. Ask what would have to be true for a different peptide to escape the same constraint, and let them discover that the answer is "not much about the peptide — everything about the delivery technology."

Bridge: this is the natural handoff into Chapter 22, and into the Part 4 arc generally. End here if you are running one session.